Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients

To be considered for this study, you would need to be between 18 and 75 years old and generally well enough to manage daily activities without much difficulty. You must have bowel cancer that has spread and doctors believe it cannot be cured with surgery alone. Your cancer also needs to have a specific genetic profile, meaning it should not have mutations in the RAS and B-RAF genes, which will be checked using a blood test.

You would not be able to join if you’ve had another type of cancer in the last five years (unless it was a very early-stage skin or cervical cancer), or if you’ve already been treated for your advanced bowel cancer. Similarly, if you’ve had certain chemotherapy drugs (like oxaliplatin) as an 'adjuvant' treatment after initial surgery, or if you have cancer that has spread to your brain, this study might not be suitable. Certain other health conditions, past serious allergic reactions to the study drugs, or if you are receiving other treatments that could interfere with the study drugs would also prevent you from taking part.

If you join this study, you will be randomly assigned to one of two treatment groups, meaning a computer will decide which drug combination you receive. Most of the treatments involve infusions (drips) that you receive in the hospital. You will have regular visits to the hospital for your treatment sessions and to monitor your health. This will include blood tests, scans (like CT scans) to check how your cancer is responding, and physical examinations. The doctors and nurses will also ask you about any side effects you might be experiencing. The overall duration of your participation will depend on how you respond to the treatment and the study plan, but you will continue to be monitored regularly. You will also have follow-up appointments even after treatment finishes, to track your long-term health and cancer status.